VaxGen CFO succession
VaxGen promotes Finance Senior Director Kevin Lee to chief financial officer after resignation of James Cunha. VaxGen is restating its financial statements for 2001 through 2003; the company has not yet filed its statements with the Securities & Exchange Commission for 2004, resulting in the company's delisting from the NASDAQ exchange. The company said Cunha's resignation was due to personal reasons and not related to the restatement process...
You may also be interested in...
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.